New hope for rare vasculitis: obinutuzumab steps in where rituximab fails
NCT ID NCT07268521
First seen Jan 06, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This phase 2 trial tests obinutuzumab, a drug similar to rituximab but possibly stronger, in 30 adults with active cryoglobulinemic vasculitis who did not improve or could not tolerate rituximab. The goal is to see if obinutuzumab can bring the disease under control and allow patients to stop steroids. It is a small, early study to check if the drug works and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOGLOBULINEMIC VASCULITIS (CV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obinutuzumab
What this could lead to
If it works, this could offer a new treatment option for people with cryoglobulinemic vasculitis who cannot use rituximab.
What could go wrong
This is a small, early-phase trial with only 30 participants. It may not show clear benefit, and obinutuzumab could cause side effects like infusion reactions or infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.